NantCell, Inc. has entered into licensing agreement with GlobeImmune, Inc. for exclusive rights to develop, manufacture and commercialize the GlobeImmune's GI-6207 program which targets the CEA protein GI-6301 program targeting the Brachyury protein. Under the terms of the agreement, GlobeImmune is entitled to receive payments on the achievement of certain product development and commercialization milestones and royalties based on net sales of products by NantCell or its affiliates or sublicensees. Concurrently, NantCell has entered into licensing agreement with GlobeImmune for exclusive worldwide rights of GI-4000. Concurrently, NantCell has exercised its option to enter into licensing agreement with GlobeImmune for exclusive worldwide rights of GI-6100.